Authors

• Susanne Isfort (ORCID: https://orcid.org/0000-0002-2855-561X)
• Steffen Koschmieder (ORCID: https://orcid.org/0000-0002-1011-8171)
• Martin Grießhammer (ORCID: https://orcid.org/0000-0001-8718-7004)
• Felix Witte (ORCID: https://orcid.org/0000-0003-4305-0713)
• Sonja Ständer (ORCID: https://orcid.org/0000-0003-3612-7786)
• Martin Metz (ORCID: https://orcid.org/0000-0002-4070-9976)
• Elke Weißhaar (ORCID: https://orcid.org/0000-0002-7016-0224)
• Svenja Müller (ORCID: https://orcid.org/0000-0002-2118-959X)
• Andreas Emanuel Kremer (ORCID: https://orcid.org/0000-0002-9263-948X)
• Claudia Zeidler (ORCID: https://orcid.org/0000-0002-9485-8627)

Institutions

• University of Zurich (CH)
• Heidelberg University (DE)
• University Hospital Heidelberg (DE)
• Medizinische Hochschule Hannover (DE)
• Universitätsklinikum Erlangen (DE)
• University Hospital of Zurich (CH)
• University Hospital Münster (DE)
• Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
• Johannes Wesling Klinikum Minden (DE)
• Charité - Universitätsmedizin Berlin (DE)
• RWTH Aachen University (DE)

Publication Details

Journal

Dermatology and Therapy

Published

2025-09-26

DOI

https://doi.org/10.1007/s13555-025-01548-2

Citations

1

Primary Topic

Myeloproliferative Neoplasms: Diagnosis and Treatment

Type

article

Field-Weighted Citation Impact

1.63

Funders

• Falk Foundation
• Amgen
• Eli Lilly and Company
• Pfizer
• AstraZeneca
• Sanofi
• Gilead Sciences
• Regeneron Pharmaceuticals
• Celldex Therapeutics
• Incyte
• Novo Nordisk
• Astellas Pharma
• Vifor Pharma
• Galderma
• Ipsen
• AOP Orphan
• Lilly Deutschland
• LEO Pharma
• Novartis Pharma
• Sanofi Genzyme
• Sanofi-Aventis Deutschland